A review of continuous vs intermittent androgen deprivation therapy: Redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a perpetual dispute-Reference-Cited by-同舟云学术

A review of continuous vs intermittent androgen deprivation therapy: Redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a perpetual dispute

Published:2014-01 Issue:1 Volume:40 Page:3-15
ISSN:1677-5538
Container-title:International braz j urol
language:
Short-container-title:Int. braz j urol.

Author:

Kratiras Zisis¹,Konstantinidis Charalampos²,Skriapas Konstantinos¹

Affiliation:

1. Koutlibanio General Hospital of Larisa (ZK, KS), Greece

2. National Rehabilitation Center (CK), Greece

Publisher

FapUNIFESP (SciELO)

Subject

Urology

Link

http://www.scielo.br/pdf/ibju/v40n1/1677-5538-ibju-40-1-0003.pdf

Reference50 articles.

1. International variation in prostate cancer incidence and mortality rates;Center MM;Eur Urol,2012

2. International epidemiology of prostate cancer: geographical distribution and secular trends;Baade PD;Mol Nutr Food Res,2009

3. 2013 online guidelines: Prostate cancer: page 82

4. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Groupstudies;Byar DP;NCI Monogr,1988

5. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research onTreatment of Cancer trials 30761 and 30762;de Voogt HJ;J Urol,1986

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection of prostate cancer therapy strategy under early androgen suppression treatment;Communications in Nonlinear Science and Numerical Simulation;2024-05

2. Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics;Cancer Research;2023-05-19

3. The sum and the parts: dynamics of multiple and individual metastases during adaptive therapy;2022-08-05

4. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update;Journal of Clinical Oncology;2021-04-10

5. LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production;PLOS ONE;2020-11-02